SEC Filing | Neuronetics Inc

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Anderson Cory

(Last)

(First)

(Middle)

C/O NEURONETICS, INC

3222 PHOENIXVILLE PIKE

(Street)

MALVERN

19355

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
07/01/2026

3. Issuer Name and Ticker or Trading Symbol
Neuronetics, Inc. [ STIM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
	Officer (give title below)	Other (specify below)
EVP & Gen. Manager, Greenbrook

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	53,205	D
Common Stock	13,336⁽¹⁾	D
Common Stock	5,001⁽²⁾	D
Common Stock	3,334⁽³⁾	D
Common Stock	55,003⁽⁴⁾	D
Common Stock	136,933⁽⁵⁾	D
Common Stock	150,000⁽⁶⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Performance Restricted Stock Unit	12/31/2026⁽⁷⁾	12/31/2027⁽⁷⁾	Common Stock	18,335⁽⁷⁾	0⁽⁸⁾	D
Performance Restricted Stock Unit	12/31/2026⁽⁹⁾	12/31/2026⁽⁹⁾	Common Stock	15,000⁽⁹⁾	0⁽⁸⁾	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award that vests on February 5, 2027, subject to the Reporting Person's continuous service with the Issuer or its affiliates through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

2. Represents a RSU award that vests on February 28, 2027, subject to the Reporting Person's continuous service with the Issuer or its affiliates through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

3. Represents a RSU award that vests on March 28, 2027, subject to the Reporting Person's continuous service with the Issuer or its affiliates through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

4. Represents a RSU award that vests in two equal annual installments beginning on February 24, 2027, in each case subject to the Reporting Person's continuous service with the Issuer or its affiliates through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

5. Represents a RSU award that vests on June 30, 2027, subject to the Reporting Person's continuous service with the Issuer or its affiliates through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

6. Represents a RSU award that vests in three equal annual installments beginning on February 23, 2027, in each case subject to the Reporting Person's continuous service with the Issuer or its affiliates through such date. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

7. Represents a performance restricted stock unit ("PRSU") award granted on February 24, 2025 and vesting beginning on December 31, 2026, subject to satisfaction of the applicable performance metrics and continuous service of the Reporting Person through such date. The performance metrics are as follows: (i) 50% of the award will be attained if the Issuer achieves Cash Balance (as defined in the applicable PRSU grant notice) for the fiscal year ended 2026 and (ii) 50% of the award will be attained if the Issuer achieves Cash Balance for the fiscal year ended 2027.

8. Each PRSU represents a contingent right to receive one share of the Issuer's common stock.

9. Represents a PRSU award granted on October 29, 2025 and vesting on December 31, 2026, subject to satisfaction of the applicable performance metrics and continuous service of the Reporting Person through such date. The performance metrics are as follows: the award will be attained if the Issuer achieves Cash Flow Breakeven (as defined in the applicable PRSU grant notice) for the fiscal quarter ended September 30, 2026.

	/s/ Patrick Devine, as Attorney-in-Fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

EX-24

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Harry Levin, Kelly Silveira, Brian Short, Suzette McNally, Patrick Devine, and W. Andrew Macan, signing singly, the undersigned’s true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of Neuronetics, Inc. (the “Company”), Form ID and/or Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID and/or Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and

(3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of June 18, 2026.

___/s/ Cory Anderson_____________

Name: Cory Anderson